Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.

Item
http://www.wikidata.org/entity/Q40688945
A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.IL-17-triggered downregulation of miR-497 results in high HIF-1α expression and consequent IL-1β and IL-6 production by astrocytes in EAE mice.CCR6+ Th cells in the cerebrospinal fluid of persons with multiple sclerosis are dominated by pathogenic non-classic Th1 cells and GM-CSF-only-secreting Th cells.Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications.Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.Psoriasis comorbidity affects multiple sclerosis neurological progression: a retrospective case - control analysis.Inflammasome Proteins As Biomarkers of Multiple Sclerosis.When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Androgen-Induced Immunosuppression.Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature
P2860

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.

Item
http://www.wikidata.org/entity/Q40688945
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Activity of secukinumab, an an ...... mized, proof-of-concept study.
@en
type
label
Activity of secukinumab, an an ...... mized, proof-of-concept study.
@en
prefLabel
Activity of secukinumab, an an ...... mized, proof-of-concept study.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Activity of secukinumab, an an ...... mized, proof-of-concept study.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P698